Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom and GlaxoSmithKline to Validate SNPs, DNA Samples Linked to Diabetes

NEW YORK, Jan 17 – Sequenom and GlaxoSmithKline have embarked upon a collaborative project to validate 500 SNPs and over 900 DNA samples from people with Type 2 Diabetes, Sequenom said Wednesday.

 

   

" Our objective is to screen hundreds of SNPs that we have localized to a

 

linkage region in order to accelerate the identification of a smaller region

 

containing a susceptibility gene for type 2 diabetes," Allen Roses,

senior vice president of genetics research at GlaxoSmithKline said in a statement.   

This collaboration is among several SNP validation partnerships in which Sequenom is currently involved.

Tuesday, the company announced its partnership with the National Cancer Institute had yielded over 3,000 new SNPs, and that the two parties were currently analyzing 10,000 additional SNPs.

Sequenom is also currently working with Gemini Genomics to look for cholesterol-related SNPs in Gemini’s twin DNA database; evaluating 700,000 SNP candidates for utility in treating cardiovascular ailments with the University of Texas-Southwestern Medical center, and has partnered with Incyte to screen

SNPs against its in-house reference human data bank of 16,000 DNA samples, and develop 100,000 SNP assays.   

Also on Tuesday, GenomeWeb reported that GlaxoSmithKline had entered an agreement to evaluate Quantum Dot's SNP detection assays.

Sequenom sees the GlaxoSmithKline collaboration as the beginning of a longer “mutually beneficial” relationship with the pharma giant.

To enhance its genotyping capabilities for this and other partnerships, Sequenom is building a new 80,000 square-foot SNP analysis facility at its San Diego headquarters. The facility, which the company expects to be operational in March, will allow Sequenom to do 10 times the amount of genotyping that it can currently perform.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.